Agonist-mediated switching of ion selectivity in TPC2 differentially promotes lysosomal function

  1. Susanne Gerndt
  2. Cheng-Chang Chen
  3. Yu-Kai Chao
  4. Yu Yuan
  5. Sandra Burgstaller
  6. Anna Scotto Rosato
  7. Einar Krogsaeter
  8. Nicole Urban
  9. Katharina Jacob
  10. Ong Nam Phuong Nguyen
  11. Meghan T Miller
  12. Marco Keller
  13. Angelika M Vollmar
  14. Thomas Gudermann
  15. Susanna Zierler
  16. Johann Schredelseker
  17. Michael Schaefer
  18. Martin Biel
  19. Roland Malli
  20. Christian Wahl-Schott  Is a corresponding author
  21. Franz Bracher  Is a corresponding author
  22. Sandip Patel  Is a corresponding author
  23. Christian Grimm  Is a corresponding author
  1. Ludwig Maximilian University of Munich, Germany
  2. UCL London, United Kingdom
  3. Medical University of Graz, Austria
  4. University of Leipzig, Germany
  5. Roche, Switzerland
  6. MHH Hannover, Germany
  7. University College London, United Kingdom

Abstract

Ion selectivity is a defining feature of a given ion channel and is considered immutable. Here we show that ion selectivity of the lysosomal ion channel TPC2, which is hotly debated (Calcraft et al., 2009; Guo et al., 2017; Jha et al., 2014; Ruas et al., 2015; Wang et al., 2012), depends on the activating ligand. A high throughput screen identified two structurally distinct TPC2 agonists. One of these evoked robust Ca2+-signals and non-selective cation currents, the other weaker Ca2+-signals and Na+-selective currents. These properties were mirrored by the Ca2+-mobilizing messenger, NAADP and the phosphoinositide, PI(3,5)P2, respectively. Agonist action was differentially inhibited by mutation of a single TPC2 residue and coupled to opposing changes in lysosomal pH and exocytosis. Our findings resolve conflicting reports on the permeability and gating properties of TPC2 and they establish a new paradigm whereby a single ion channel mediates distinct, functionally-relevant ionic signatures on demand.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Susanne Gerndt

    Pharmacy, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Cheng-Chang Chen

    Pharmacology, Ludwig Maximilian University of Munich, München, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1282-4026
  3. Yu-Kai Chao

    Walther-Straub-Institute of Pharmacology and Toxicology, LM-University Munich, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1202-2448
  4. Yu Yuan

    Biosciences, UCL London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Sandra Burgstaller

    Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria
    Competing interests
    The authors declare that no competing interests exist.
  6. Anna Scotto Rosato

    Medicine, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Einar Krogsaeter

    Medicine, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8232-5498
  8. Nicole Urban

    Pharmacology/Medicine, University of Leipzig, Leipzig, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Katharina Jacob

    Medicine, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Ong Nam Phuong Nguyen

    Pharmacy, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  11. Meghan T Miller

    HTS, Roche, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  12. Marco Keller

    Pharmacy, Ludwig Maximilian University of Munich, München, Germany
    Competing interests
    The authors declare that no competing interests exist.
  13. Angelika M Vollmar

    Pharmacy, Ludwig Maximilian University of Munich, München, Germany
    Competing interests
    The authors declare that no competing interests exist.
  14. Thomas Gudermann

    Medicine, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  15. Susanna Zierler

    Walther-Straub Institute of Pharmacology and Toxicology, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4684-0385
  16. Johann Schredelseker

    Walther Straub Institute of Pharmacology and Toxicology, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6657-0466
  17. Michael Schaefer

    Rudolf-Boehm-Institute for Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany
    Competing interests
    The authors declare that no competing interests exist.
  18. Martin Biel

    Pharmacy, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  19. Roland Malli

    Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6327-8729
  20. Christian Wahl-Schott

    Medicine, MHH Hannover, Hannover, Germany
    For correspondence
    wahl-schott.christian@mh-hannover.de
    Competing interests
    The authors declare that no competing interests exist.
  21. Franz Bracher

    Pharmacy, Ludwig Maximilian University of Munich, München, Germany
    For correspondence
    franz.bracher@cup.uni-muenchen.de
    Competing interests
    The authors declare that no competing interests exist.
  22. Sandip Patel

    Cell and Developmental Biology, University College London, London, United Kingdom
    For correspondence
    patel.s@ucl.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
  23. Christian Grimm

    Department of Pharmacy, Ludwig Maximilian University of Munich, Munich, Germany
    For correspondence
    Christian.Grimm@med.uni-muenchen.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0177-5559

Funding

Mucolipidosis IV Foundation (MDBR-17-120- ML4)

  • Christian Grimm

Deutsche Forschungsgemeinschaft (SFB/TRR152 P04)

  • Christian Grimm

Deutsche Forschungsgemeinschaft (SFB/TRR152 P06)

  • Christian Wahl-Schott

Deutsche Forschungsgemeinschaft (SFB/TRR152 P12)

  • Martin Biel

Deutsche Forschungsgemeinschaft (BR 1034/7-1)

  • Franz Bracher

Biotechnology and Biological Sciences Research Council (BB/N01524X/1)

  • Sandip Patel

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Bavarian Government and the European Union. All of the animals were handled according to approved institutional animal care protocols of the University of Munich. The protocol was approved by the Bavarian Government (AZ55.2-1-54-2532-170-17).

Copyright

© 2020, Gerndt et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,564
    views
  • 950
    downloads
  • 124
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

Share this article

https://doi.org/10.7554/eLife.54712

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Angel D'Oliviera, Xuhang Dai ... Jeffrey S Mugridge
    Research Article

    The SARS-CoV-2 main protease (Mpro or Nsp5) is critical for production of viral proteins during infection and, like many viral proteases, also targets host proteins to subvert their cellular functions. Here, we show that the human tRNA methyltransferase TRMT1 is recognized and cleaved by SARS-CoV-2 Mpro. TRMT1 installs the N2,N2-dimethylguanosine (m2,2G) modification on mammalian tRNAs, which promotes cellular protein synthesis and redox homeostasis. We find that Mpro can cleave endogenous TRMT1 in human cell lysate, resulting in removal of the TRMT1 zinc finger domain. Evolutionary analysis shows the TRMT1 cleavage site is highly conserved in mammals, except in Muroidea, where TRMT1 is likely resistant to cleavage. TRMT1 proteolysis results in reduced tRNA binding and elimination of tRNA methyltransferase activity. We also determined the structure of an Mpro-TRMT1 peptide complex that shows how TRMT1 engages the Mpro active site in an uncommon substrate binding conformation. Finally, enzymology and molecular dynamics simulations indicate that kinetic discrimination occurs during a later step of Mpro-mediated proteolysis following substrate binding. Together, these data provide new insights into substrate recognition by SARS-CoV-2 Mpro that could help guide future antiviral therapeutic development and show how proteolysis of TRMT1 during SARS-CoV-2 infection impairs both TRMT1 tRNA binding and tRNA modification activity to disrupt host translation and potentially impact COVID-19 pathogenesis or phenotypes.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Qian Wang, Jinxin Liu ... Qian Liu
    Research Article

    Paramyxovirus membrane fusion requires an attachment protein for receptor binding and a fusion protein for membrane fusion triggering. Nipah virus (NiV) attachment protein (G) binds to ephrinB2 or -B3 receptors, and fusion protein (F) mediates membrane fusion. NiV-F is a class I fusion protein and is activated by endosomal cleavage. The crystal structure of a soluble GCN4-decorated NiV-F shows a hexamer-of-trimer assembly. Here, we used single-molecule localization microscopy to quantify the NiV-F distribution and organization on cell and virus-like particle membranes at a nanometer precision. We found that NiV-F on biological membranes forms distinctive clusters that are independent of endosomal cleavage or expression levels. The sequestration of NiV-F into dense clusters favors membrane fusion triggering. The nano-distribution and organization of NiV-F are susceptible to mutations at the hexamer-of-trimer interface, and the putative oligomerization motif on the transmembrane domain. We also show that NiV-F nanoclusters are maintained by NiV-F–AP-2 interactions and the clathrin coat assembly. We propose that the organization of NiV-F into nanoclusters facilitates membrane fusion triggering by a mixed population of NiV-F molecules with varied degrees of cleavage and opportunities for interacting with the NiV-G/receptor complex. These observations provide insights into the in situ organization and activation mechanisms of the NiV fusion machinery.